###### Strengths and limitations of this study

-   Cohort study comprised of patients with cardiologist-confirmed diagnoses, high rates of case ascertainments and prompt mortality updates.

-   Meta-analysis portion of the study adhered to the Preferred Reporting Items for Systematic Review and Meta-analyses Protocols.

-   Large sample size and event rates and longer-term follow-up allowed detailed assessment of the association of hyperlipidemia (HLP) with mortality across multiple categories.

-   1:1 propensity scoring was used to match pairs of patients with concurrent HLP and those with no HLP for potential confounders.

-   Limitations were inherent disadvantages of retrospective cohort studies, potential unmeasured confounders, *International Classification of Diseases, Ninth Revision, Clinical Modification* to identify study cohorts, ascertainment of comorbid conditions during index hospitalisation and lack of data on subsequent acquisition of these conditions during the follow-up.

Introduction {#s1}
============

Early epidemiological studies of 1970s and 1980s including Framingham Heart Study,[@R1] Multiple Risk Factor Intervention Trial,[@R2] Coronary Primary Prevention Study,[@R3] and Helsinki Heart Study,[@R4] all provided substantial evidence for the epidemiological relationship between cholesterol levels and incident coronary artery disease in general population. In 2007, a meta-analysis of individual data from 61 prospective studies suggested that total cholesterol was positively associated with cardiovascular mortality.[@R5] However, contemporary studies largely examined the effect of statins and other cholesterol lowering interventions on cardiovascular events.[@R6] A similar relationship between hyperlipidemia (HLP) and incident heart failure (HF) has been reported.[@R6] Surprisingly, several recent studies found an inverse association where HLP, counterintuitively, conferred an overall survival benefit in patients with established acute myocardial infarction (AMI)[@R10] and HF.[@R14] Although cholesterol levels in general population predict new cardiovascular events, it is unclear whether a positive association persists after incident AMI or HF. Furthermore, the effect of HLP on the association of other competing conditions with mortality is unknown.

Systematic reviews and meta-analyses on the association of HLP with new AMI have already been published,[@R5] but the clinical trials evaluating this relationship after the incident AMI have not been systematically reviewed. Additionally, the data are limited on the association between HLP and incident HF and subsequent mortality. A comprehensive review of published data on the association of HLP with mortality after incident AMI or HF would clarify these issues.

We postulated that if a diagnosis of HLP decreases the mortality after AMI or HF, then, it also lessens the magnitude of mortality risks associated with other competing comorbidities. We tested this hypothesis, separately, in large cohorts of patients hospitalised for incident AMI and acute decompensated HF (ADHF). To compare patients with and with no HLP, we assembled 1:1 balanced groups using propensity score-matching for each study condition. Our objectives were three-fold: (1) to estimate the association of HLP with all-cause mortality among patients with AMI or ADHF, (2) to determine the extent to which the association between other competing comorbidities[@R15] and mortality is modified by HLP (3) and to provide risk estimates for mortality associated with HLP after incident AMI or HF through systematic review and meta-analyses of published and current study data to place the current findings in the context of published literature.

Methods {#s2}
=======

Cohort study {#s2-1}
------------

### Study population and data collection {#s2-1-1}

The study cohorts were comprised of adults aged ≥18 years, hospitalised at Mayo Clinic from August 1, 1996 to September 17, 2015 with primary discharge diagnoses of AMI or ADHF with follow-up completed through August 17, 2016. AMI included both ST-elevation myocardial infarction (STEMI) and non-STEMI. ADHF comprised of HF with both reduced and preserved ejection fractions. Discharge diagnoses were identified by the *International Classification of Diseases, Ninth Revision, Clinical Modification* (ICD-9-CM) codes (presented in [online supplementary table 1](#SP1){ref-type="supplementary-material"}). Mayo Clinic has one of the oldest and most advanced medical record systems in the USA. Patient provided information is constantly updated at every clinic or hospital visit at its main Rochester campus and at a network of clinics and hospitals across more than 60 communities in states of Iowa, Wisconsin and Minnesota. Strengthening The Reporting of Observational studies in Epidemiology (STROBE) flow diagram of study cohorts' selection of is presented in [online supplementary figure 1](#SP1){ref-type="supplementary-material"}. Further details of data extraction are published elsewhere.[@R16] The study was approved by the Mayo Clinic Institutional Review Board and need for patient consent was waived.
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### Ascertainment of AMI and ADHF {#s2-1-2}

For each patient the primary discharge diagnosis, AMI or ADHF, was documented by the attending physician at the time of discharge, assigned ICD-9-CM code, and subsequently captured by the abstractors.

### Ascertainment of comorbid conditions {#s2-1-3}

We focused on a panel of 20 comorbid conditions CCs defined by Department of Health and Human Services[@R15] and identified by Clinical Classifications Software codes of US Healthcare Cost Utilization Project. CCs with prevalence \<3% were excluded from analysis. To ascertain the comorbid effect of HLP on other concurrent condition, we paired HLP with other competing comorbidities within an individual patient.

### Ascertainment of HLP and statin use {#s2-1-4}

HLP was defined as having a pre-existing or a new in-hospital diagnosis based on low density lipoprotein cholesterol (LDL-C) level ≥100 mg/dL as clinically measured during index hospitalisation or within the preceding 6 months. LDL-C was measured indirectly by Friedewald method.[@R17] Published reports suggest that lipid panel measured during the first 24 hours after an acute cardiovascular event reliably represents baseline level.[@R18] Statin use was based on discharge medication reconciliation.

### Ascertainment of mortality {#s2-1-5}

All deaths occurring from admission to censoring date of August 17, 2016 were abstracted from medical records. The mortality data is updated regardless of the cause of death, including death due to murders, suicides, or accidents. At the time of drafting the manuscript, Minnesota all-cause (including suicide, murder, misadventures and natural) Electronic Death Certificate Data is current to December 31, 2018,

Patient follow-up {#s2-2}
-----------------

All patients were followed from index hospitalisation until death or censoring date of August 17, 2016 whichever occurred first.

Patient and public involvement {#s2-3}
------------------------------

Patients and public were not involved in this study

Systematic review and meta-analysis {#s2-4}
-----------------------------------

### Data source and searches {#s2-4-1}

This systematic review and meta-analysis was conducted in accordance with the established methods[@R19] and followed Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines.[@R20] We searched of MEDLINE, EMBASE, Cochrane Library, Web of Science databases for eligible trials from inception through September 2017 with continued surveillance through February 2018 for trials examining the associations of HLP with mortality. We identified clinical studies with the same population, condition/disease, intervention, control and at least one outcome and objectives. Studies with incomplete data were excluded. Methodological details of the meta-analysis are published elsewhere.[@R21] The search strategy is presented in the supplement.

Study selection {#s2-5}
---------------

Eligibility criteria included: (1) randomised or non-randomised clinical trials of adults with AMI or HF, (2) comparator groups HLP or hypercholesterolemia versus no HLP or no hypercholesterolemia as defined by individual study investigators and (3) mortality as the primary outcome or one of the outcomes.

Data extraction and risk of bias assessment {#s2-6}
-------------------------------------------

From the results of initial search, two investigators (EA and HA), working independently reviewed articles for eligibility on the basis of titles and abstracts. Studies that satisfied the inclusion and exclusion criteria were retrieved for full text review. Disagreements were resolved by consensus and retained conflicts were adjudicated by a third investigator (MY). We extracted the following data from each study: type of study, number of participants, age, gender, presence and absence of HLP, length of follow-up and outcome measures. Measure of association with clinical outcomes (HR, OR), or relative risk (RR)) were abstracted. Risk of bias was assessed using the Newcastle-Ottawa Scale for cohort studies.[@R22]

Statistical analysis {#s2-7}
--------------------

ALL Statistical analyses were performed using SAS V.9.4.

### The cohort study {#s2-7-1}

*Propensity score analysis* [@R23]: We assembled 1:1 propensity score-matched pairs of patients with AMI or ADHF to balance the differences in baseline variables between patients with and without concurrent HLP. Propensity scores were estimated using logistic regression (PROC PS MATCH in SAS) based on age, gender, length of stay, race, comorbidities, statin prescription on discharge and time period (1996--2005 vs 2006--2016). Standardised differences in the matched cohort ranged from 0.122 to 0.004. One-to-one nearest neighbour calliper matching was used to match patients based on the propensity score using a calliper equal to 0.2 of the SD of the logit of the propensity score. We performed C-statistic as a measure of the ability of the propensity score to control confounders.[@R24] C-statistic for the model was 0.752 for AMI patients and 0.755 for HF patients. Patients were of exact match on gender, race and enrollment period. Patients without HLP were matched to one with HLP generating a quasi-randomised design whereby study groups (HLP vs no HLP) have had similar propensity for allocation to either group.

*Kaplan-Meier estimates:* Kaplan-Meier estimates were performed using propensity-score matched cohorts and stratified log-rank tests were used to compare survival curves.

*Multivariable Cox models*: Cox proportional hazards models were performed on the matched samples using a robust variance estimator to account for matching. Multiple models were constructed for estimating HR for mortality. Model 1 estimated HR and 95% CI for mortality associated with HLP and other CCs. Model 2 was extended to fit Model 1 plus statin therapy. Model 3 examined the comorbid effect of HLP in combination with other competing comorbidities.

*Sensitivity analysis:* We performed several sensitivity analyses to ascertain the degree of bias that might explain significant associations between HLP and mortality and to confirm the robustness of our findings. From propensity-score matched AMI and HF patients, we identified patients with available data related to body mass index (BMI), LDL-C, left ventricular ejection fraction (LVEF) and serum concentrations of sodium, blood urea nitrogen (BUN), and creatinine. We conducted sensitivity analyses using separate Cox proportional regression models by excluding (1) patients with no LDL-C data, (2) patients with no available data on levels of sodium, BUN and creatinine, (3) patients with no available data on BMI and (4) patients with no available data on LVEF.

### The meta-analysis {#s2-7-2}

The DerSimonian and Laird random-effects model was used to pool estimates across studies.[@R25] The results were expressed as RR and 95% CI. Heterogeneity was assessed using *I* [@R2] to reflect proportion of heterogeneity not attributable to chance.[@R26] The number of studies was insufficient to statistically evaluate publication bias. Characteristics of included studies ([online supplementary table 2](#SP1){ref-type="supplementary-material"}), assessment of risk of bias ([online supplementary table 3](#SP1){ref-type="supplementary-material"}) and PRISMA flow diagram ([online supplementary figure 2](#SP1){ref-type="supplementary-material"}) are presented in supplement. PRISMA check list is presented in [online supplementary table 4](#SP1){ref-type="supplementary-material"}. We pooled the effect sizes (in this case, HR) reported by the studies. We did not pool the intercept of the models as most were not reported. Additionally, the methods to generate the pooled intercept are not well developed either.

Results {#s3}
=======

The cohort study {#s3-1}
----------------

### Cohort study population {#s3-1-1}

The [online supplementary figure 1](#SP1){ref-type="supplementary-material"} illustrates the STROBE flow diagram for selection of final study cohorts: AMI (initial cohort n=13 680; propensity score-matched cohort n=8696, pairs 4348) and ADHF (Initial cohort n=9717; propensity score-matched cohort n=5758, pairs 2879). STROBE checklist is presented in [online supplementary table 5](#SP1){ref-type="supplementary-material"}.

### Baseline characteristics {#s3-1-2}

Baseline characteristics for each study cohort, before and after propensity score-matching by HLP, are presented in [table 1](#T1){ref-type="table"}. Baseline characteristics for matched patients in each cohort were balanced. Before matching, patients with HLP were younger, more likely to be males, and had lower rates of chronic obstructive pulmonary disease (COPD) and HF and high prevalence of chronic kidney disease (CKD) and hypertension in the AMI cohort. As these variables were balanced in propensity score-matching, a balanced cohort with standardised differences of \<10% for baseline characteristics was created for final analysis. [online supplementary figure 3](#SP1){ref-type="supplementary-material"} illustrates a love plot of standardised differences before and after propensity-score matching to allow visualisation of improvement in prognostic balance. Of 20 CCs, only eight were included in final analysis for frequency ≥3%. [Online supplementary tables 4 and 5](#SP1){ref-type="supplementary-material"} represent PRISMA

###### 

Patient characteristics and standardised differences before and after propensity score-matching

  ------------------------------------------------------------------------------------------------------------------------------------------
  Acute myocardial infarction                                                                                                        
  ----------------------------- ---------------------------------------- ------------ ------------ ------- ------------ ------------ -------
  Demographics                  Age, years, mean±SD                      67.0±13.6    71.3±13.5    0.315   68.9±13.3    70.6±13.6    0.122

                                Male n (%)                               6035 (68)    2938 (62)    0.121   2761 (64)    2761 (64)    0

                                White n (%)                              8108 (91)    3963 (83)    0.222   3744 (86)    3744 (86)    0

  Anthropometric measurements   BMI kg/m^2^                              30.1±6.2     28.8±6.3     --      29.8±6.3     28.9±6.3     --

                                BMI, missing n = (%)                     1556 (17)    1520 (32)    --      1274 (29)    1330 (31)    --

  Clinical characteristics      LOS, days, median (quartiles 25%--75%)   3 (2--5)     4 (3--8)     0.275   4 (3--6)     4 (3--7)     0.086

  Year of hospital admission    1996--2005 n (%)\                        3886 (44)\   3732 (79)\   0.770   3341 (77)\   3341 (77)\   0
                                2006--2016 n (%)                         5043 (57)    1019 (21)            1007 (23)    1007 (23)    

  Comorbid conditions           CAD, n (%)                               --           --                   --           --           

                                Cancer, n (%)                            744 (8)      342 (7)      0.042   279 (6)      313 (7)      0.029

                                CKD, n (%)                               885 (12)     380 (8)      0.067   348 (18)     353 (8)      0.004

                                COPD, n (%)                              820 (9)      640 (14)     0.136   482 (11)     543 (13)     0.044

                                Diabetes, n (%)                          2567 (29)    1249 (26)    0.055   1091 (295)   1149 (26)    0.030

                                Heart failure, n (%)                     1762 (20)    1376 (29)    0.216   1033 (24)    1173 (27)    0.075

                                Hypertension, n (%)                      6049 (68)    2584 (54)    0.277   2530 (58)    2453 (56)    0.037

                                Stroke, n (%)                            359 (4)      168 (4)      0.025   151 (4)      148 (3)      0.004

  Lipid levels                  LDL-C mg/dl                              110.9±39.2   78.7±25.0    --      118.4±37.6   78.8±25.1    --

                                LDL-C, missing n (%)                     483 (5)      1356 (29)    --      251 (6)      1177 (27)    --

  Drug treatment                Statin                                   4665 (52)    1431 (30)    0.461   1566 (36)    1412 (33)    0.074
  ------------------------------------------------------------------------------------------------------------------------------------------

  ------------------------------------------------------------------------------------------------------------------------------------------
  Heart failure                                                                                                                      
  ----------------------------- ---------------------------------------- ------------ ------------ ------- ------------ ------------ -------
  Demographics                  Age, years, mean±SD                      73.2±12.4    73.0±14.5    0.020   72.6±12.6    73.1±14.1    0.040

                                Male n (%)                               2342 (59)    3266 (57)    0.058   1682 (54)    1682 (54)    0

                                White n (%)                              3574 (91)    4896 (85)    0.181   2588 (90)    2588 (90)    0

  Anthropometric measurements   BMI kg/m^2^                              31.1±7.6     29.7±7.5     --      31.0±7.6     30.0±7.5     --

                                BMI, missing n (%)                       193 (5)      780 (13)     --      185 (6)      262 (9)      --

  Clinical characteristics      LOS, days, median (quartiles 25%--75%)   4 (2--6)     4 (2--7)     0.183   4 (2--6)     4 (2--7)     0.018

  Year of hospital admission    1996--2005 n (%)\                        1221 (31)\   3510 (61)\   0.626   1197 (42)\   1197 (42)\   0
                                2006--2016 n (%)                         2720 (69)    2266 (39)            1682 (58)    1682 (58)    

  Comorbid conditions           CAD, n (%)                               2482 (63)    2309 (40)    0.472   1580 (55)    1537 (53)    0.031

                                Cancer, n (%)                            595 (15)     736 (13)     0.068   419 (15)     420 (15)     0.001

                                CKD, n (%)                               1286 (33)    1299 (23)    0.228   802 (28)     819 (28)     0.013

                                COPD, n (%)                              813 (21)     1152 (20)    0.017   567 (20)     584 (20)     0.015

                                Diabetes, n (%)                          1617 (41)    1660 (29)    0.260   1117 (39)    1015 (35)    0.075

                                Heart failure, n (%)                     --           --           --      --           --           --

                                Hypertension, n (%)                      2911 (74)    2930 (51)    0.492   1931 (67)    1869 (65)    0.046

                                Stroke, n (%)                            160 (4)      106 (2)      0.132   94 (3)       75 (3)       0.039

  Lipid levels                  LDL-C mg/dl                              92.8±39.9    75.5±28.5    --      98.5±41.0    74.0±28.5    --

                                LDL-C, missing n (%)                     517 (13)     2130 (37)    --      268 (13)     928 (32)     --

  Drug treatment                Statin                                   1731 (44)    963 (17)     0.621   906 (32)     800 (28)     0.084
  ------------------------------------------------------------------------------------------------------------------------------------------

BMI, body mass index; CAD, coronary artery disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; LDL-C, low-density lipoprotein cholesterol; LOS, length of stay.

Mortality {#s3-2}
---------

*AMI*: In matched patients, mortality was significantly lower among patients with HLP versus those with no HLP (overall mortality 2182 (50.2%) vs 2718 (62.5%) or 5.9 vs 8.6 deaths/100 person-years of follow-up, p\<0.0001). Median and person-years of follow-up was greater in matched patients with HLP (median 8.8 years, IQ 3.2--13.1 years, 37 068 person-years of follow-up) versus those with no HLP (median 6.3 years, IQ 1.4--12.4 years, 31 569 person-years of follow-up).

*ADHF*: In matched patients, mortality was significantly lower among patients with HLP versus those with no HLP (overall mortality 1687 (58.6%) vs 1948 (67.7%) or 12.4 vs 16.3 deaths/100 person-years of follow-up, p\<0.0001). Median and person-years of follow-up was greater in matched patients with HLP (Follow-up: median 3.2 years, IQ 1.0--6.9 years, 13 577 person-years of follow-up) versus those with no HLP (median 2.5 years, IQ 0.7--6.2 years, 11 951 person-years of follow-up).

Kaplan-Meier estimates {#s3-3}
----------------------

[Figure 1](#F1){ref-type="fig"} displays Kaplan-Meier estimates of all-cause mortality by HLP in propensity-score matched samples of AMI or ADHF patients. Kaplan-Meier survival curves diverged immediately after hospitalisation and then remained parallel during the follow-up in both AMI and ADHF cohorts. Log-rank p value for patients with and with no HLP remained \<0.0001 for each index condition. In multiple subanalyses, risk differences in mortality between patients with and without HLP persisted in age \<65 and ≥65 years, male and female, white and non-White with log-rank p\<0.0001 for all sub-groups.

![Kaplan-Meier estimates, cumulative incidence of death in propensity-score matched patients. ADHF, acute decompensated heart failure; AMI, acute myocardial infarction; HLP, hyperlipidemia; LDL-C, low density lipoprotein cholestrol.](bmjopen-2018-028638f01){#F1}

Cox proportional regression model 1 {#s3-4}
-----------------------------------

The results are presented in [figure 2](#F2){ref-type="fig"}. HLP as compared with no HLP, was associated with a lower risk of death from any cause after AMI (HR 0.76, 95% CI (CI) 0.72--0.80, n=8696) or ADHF (HR 0.80, 95% CI 0.75 to 0.86, n=5758). Findings did not change significantly with exclusion of patients with a new in-hospital HLP diagnosis in sensitivity analysis. Co-occurrence of cancer, CKD, COPD, diabetes mellitus, HF, or stroke independently increased mortality following AMI or ADHF. While hypertension reduced mortality by 8% (95% CI 0.87 to 0.98) after AMI, neither hypertension nor coronary artery disease influenced mortality after ADHF hospitalisation.

![Cox proportional hazard regression models and forest plot. HR and 95% CI for all-cause mortality. CAD, coronary artery disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; HLP, hyperlipidemia; HTN, hypertension; LOS, length of stay.](bmjopen-2018-028638f02){#F2}

Cox proportional regression model 2 {#s3-5}
-----------------------------------

In separate analysis, adjustment of Cox proportional model for statin treatment did not change results for baseline HLP in predicting the all-cause mortality (AMI: HR 0.69, 95% CI 0.65 to 0.73; ADHF: HR 0.78, 95% CI 0.73 to 0.83).

Cox proportional regression model 3 {#s3-6}
-----------------------------------

The results of Cox model 3 are shown in [figure 2](#F2){ref-type="fig"}. Magnitude of HRs for mortality associated with cancer, COPD, CKD, diabetes, HF and stroke were all modestly attenuated with concurrent HLP across study cohorts. By comparison, protective effect of HLP on mortality was enhanced when paired with hypertension (HTN) in both AMI (HR 0.77, 95% CI 0.72 to 0.83) and ADHF (HR 0.86, 95% CI 0.78 to 0.94).

Sensitivity analysis with available data on following covariates {#s3-7}
----------------------------------------------------------------

1.  *BMI*: Of 8646 patients with AMI 6092, and of 5758 patients with HF, 5311 have data for BMI. The association of HLP with mortality remained unchanged when multivariable model accounted for BMI. BMI was inversely related to mortality with one unit increase in BMI resulting in 1% reduction in mortality in both AMI (HR 0.99, 95% CI 0.98 to 0.99, p=0.0130) and HF (HR 0.99, 95% CI 0.98 to 0.99, p\<0.0001) cohorts ([table 2](#T2){ref-type="table"})

2.  *LDL-C on or within 6 months preceding admission:* Overall, 7268 patients (84%) in AMI cohort and 4562 patients (79%) in HF cohort had LDL-C clinically measured on or within 6 months preceding hospitalisation. We stratified patients into quartiles according to levels of LDL-C,\<70 mg/dL, 70--99 mg/dL, 100--129 mg/dL and ≥130 mg/dL. There was a graded reduction in mortality from highest to the lowest LDL-C quartile in both AMI and HF ([table 2](#T2){ref-type="table"}).

3.  *Levels of sodium, BUN and creatinine*. AMI: 7603 (87%), 6609 (70%) and 7812 (90%) had data available on sodium, BUN and creatinine respectively. HLP remained an independent predictor of lower mortality compared with no HLP when accounted for levels of sodium (≤135 vs\>135 mmol/L), BUN (≤19 vs\>19) and creatinine (≤1.5 vs\>1.5) ([table 2](#T2){ref-type="table"}). HF: 7603 (87%), 6609 (70%) and 7812 (90%) had data available on sodium, BUN and creatinine respectively. HLP remains an independent predictor of lower mortality compared with no HLP when accounted for levels of sodium (≤135 vs\>135 mmol/L), BUN (≤19 vs\>19) and creatinine (≤1.5 vs\>1.5) ([table 2](#T2){ref-type="table"}).

4.  *LVEF:* A total of 5408 patients (62%) with AMI and 3869 patients (67%) patients with ADHF had data available on LVEF, measured clinically during or within 6 months preceding hospitalisation. HLP remained an independent predictor of lower mortality compared with no HLP when adjusted for LVEF in AMI and ADHF ([table 2](#T2){ref-type="table"}).

###### 

Results of four sensitivity analysis by separate COX proportional regression models among patients with acute myocardial infarction or heart failure in whom the relevant data point were available. Model 1, propensity-score matched patients with available data on BMI; model 2, propensity-score matched patients with available data on LVEF; model 3, propensity-score matched patients with available data on LDL-C measured on admission or within the preceding 6 months; model 4, propensity-score matched patients with available data on sodium, BUN and creatinine levels measured on admission.

  Acute myocardial infarction                                                                                                   
  ---------------------------------- ------------------------------ ----------------------------- ----------------------------- -----------------------------
  Age                                1.06 (1.05 to 1.06)\<0.0001    1.07 (1.06 to 1.07)\<0.0001   1.06 (1.05 to 1.06)\<0.0001   1.06 (1.05 to 1.06)\<0.0001
  Gender                             1.06 (0.99 to 1.14) 0.1123     1.04 (0.96 to 1.13) 0.3128    1.07 (0.99 to 1.14) 0.0650    1.07 (0.96 to 1.11) 0.3931
  Ethnicity                          0.79 (0.71 to 0.89) 0.0001     0.76 (0.65 to 0.89) 0.0006    0.735 (0.67 to 0.87) 0.9286   0.83 (0.75 to 0.92) 0.0003
  Length of stay                      1.01 (1.01 to 1.02)\<0.0001   1.01 (1.01 to 1.02)\<0.0001   1.02 (1.01 to 1.02)\<0.0001   1.00 (0.99 to 1.01) 0.1374
  Cancer versus no cancer            1.82 (1.62 to 2.05)\<0.0001    2.08 (1.82 to 2.39)\<0.0001   1.77 (1.57 to 1.99)\<0.0001   1.76 (1.56 to 1.99)\<0.0001
  CKD versus no CKD                  1.67 (1.49 to 1.86)\<0.0001    1.88 (1.66 to 2.13)\<0.0001   1.47 (1.31 to 1.64)\<0.0001    
  COPD versus no COPD                1.64 (1.50 to 1.81)\<0.0001    1.78 (1.60 to 1.98)\<0.0001   1.75 (1.60 to 1.91)\<0.0001   1.58 (1.44 to 1.74)\<0.0001
  DM versus no DM                    1.48 (1.37 to 1.60)\<0.0001    1.51 (1.51 to 1.39)\<0.0001   1.45 (1.35 to 1.56)\<0.0001   1.38 (1.28 to 1.49)\<0.0001
  HLP versus no HLP                  0.74 (0.70 to 0.80)\<0.0001    0.77 (0.72 to 0.83)\<0.0001                                 0.76 (0.71 to 0.82)\<0.0001
  HF versus no HF                    1.65 (1.52 to 1.78)\<0.0001    1.54 (1.40 to 1.69)\<0.0001   1.65 (1.54 to 1.78)\<0.0001   1.55 (1.43 to 1.68)\<0.0001
  HTN versus no HTN                  0.96 (0.89 to 1.03) 0.3022     1.01 (0.93 to 1.09) 0.8735    0.95 (0.89 to 1.02) 0.1532    0.85 (0.79 to 0.91)\<0.0001
  Stroke versus no stroke            1.32 (1.12 to 1.57) 0.0004     1.20 (0.98 to 1.46) 0.0735    1.28 (1.09 to 1.51) 0.0060    1.45 (1.23 to 1.71)\<0.0001
  BMI                                0.99 (0.98 to 0.99) 0.0130                                                                  
  LVEF \<50% versus≥50%                                             1.36 (1.26 to 1.48)\<0.0001                                  
  Sodium,≤135 versus\>135 mmol/L                                                                                                1.12 (1.03 to 1.22) 0.0055
  BUN ≤19 versus≥20 mg/dL                                                                                                       0.79 (0.73 to 0.85)\<0.0001
  Creatinine≤1.5 versus\>1.5 mg/dL                                                                                              0.66 (0.55 to 0.66)\<0.0001
  LDL-C, Q2 versus Q1                                                                             0.90 (0.83 to 0.99) 0.0240     
  LDL-C, Q3 versus Q1                                                                             0.87 (0.79 to 0.95)\<0.0033    
  LDL-C, Q4 versus Q1                                                                             0.83 (0.75 to 0.92)\<0.0003    

  HF                                                                                                                            
  ----------------------------------- ----------------------------- ----------------------------- ----------------------------- -----------------------------
  Age                                 1.03 (1.03 to 1.04)\<0.0001   1.04 (1.04 to 1.05)\<0.0001   1.03 (1.03 to 1.04)\<0.0001   1.04 (1.03 to 1.04)\<0.0001
  Gender                              1.10 (1.03 to 1.19) 0.0010    1.11 (1.01 to 1.21) 0.0264    1.07 (0.98 to 1.15) 0.1144    1.02 (0.93 to 1.11)\<0.0001
  Ethnicity                           1.18 (1.04 to 1.35) 0.0119    1.05 (0.87 to 1.25) 0.6243    1.14 (1.00 to 1.31)\<0.0462   1.13 (0.97 to 1.32) 0.1155
  Length of stay                      1.02 (1.01 to 1.02)\<0.0001   1.02 (1.01 to 1.02)\<0.0001   1.02 (1.01 to 1.02)\<0.0001   1.04 (1.01 to 1.02) 0.0005
  Cancer versus no cancer             1.43 (1.30 to 1.57)\<0.0001   1.44 (1.28 to 1.62)\<0.0001   1.34 (1.19 to 1.49)\<0.0001   1.41 (1.25 to 1.59)\<0.0001
  CKD versus no CKD                   1.50 (1.39 to 1.62)\<0.0001   1.72 (1.56 to 1.89)\<0.0001   1.48 (1.36 to 1.62)\<0.0001    
  COPD versus no COPD                 1.16 (1.07 to 1.26) 0.0004    1.25 (1.13 to 1.39)\<0.0001   1.19 (1.08 to 1.30) 0.0002    1.23 (1.11 to 1.36)\<0.0001
  DM versus no DM                     1.14 (1.06 to 1.23) 0.0005    1.13 (1.03 to 1.23) 0.0068    1.08 (1.00 to 1.17) 0.0450    1.08 (0.99 to 1.18) 0.0769
  HLP versus no HLP                   0.81 (0.76 to 0.87)\<0.0001   0.83 (0.76 to 0.90)\<0.0001                                 0.78 (0.72 to 0.85)\<0.0001
  CAD versus no CAD                   1.03 (0.96 to 1.10) 0.4144    1.04 (0.96 to 1.14) 0.3457    1.02 (0.94 to 1.11) 0.5854    1.05 (0.96 to 1.14) 0.2684
  HTN versus no HTN                   0.97 (0.90 to 1.05) 0.4229    0.99 (0.90 to 1.08) 0.8029    0.95 (0.87 to 1.03) 0.2073    0.83 (0.85 to 1.02) 0.1386
  Stroke versus no stroke             1.05 (0.86 to 1.28) 0.6273    1.17 (0.94 to 1.46) 0.1605    1.06 (0.86 to 1.30) 0.5812    1.01 (0.80 to 1.28) 0.9253
  BMI                                 0.99 (0.98 to 0.99)\<0.0001                                                                
  LVEF \<50% versus≥50%                                             1.07 (0.98 to 1.17) 0.1328                                   
  Sodium,≤135 versus\>135 mmol/L                                                                                                1.35 (1.23 to 1.48)\<0.0001
  BUN ≤19 versus≥20 mg/dL                                                                                                       0.83 (0.74 to 0.92) 0.0007
  Creatinine \<1.5 versus≥1.5 mg/dL                                                                                             0.76 (0.70 to 0.84)\<0.0001
  LDL-C, Q2 versus Q1                                                                             0.89 (0.81 to 0.98) 0.0197     
  LDL-C, Q3 versus Q1                                                                             0.82 (0.74 to 0.92)\<0.0003    
  LDL-C, Q4 versus Q1                                                                             0.77 (0.68 to 0.87)\<0.0001    

BMI, body mass index; BUN, blood urea nitrogen; CAD, coronary artery disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; HF, heart failure; HLP, hyperlipidemia; HTN, hypertension; LDL-C, low-density lipoprotein cholesterol; LVEF, left ventricular ejection fraction; Q, quartile.

[Meta-analysis]{.ul} {#s3-8}
--------------------

HLP was associated with lower all-cause mortality after AMI (≤30 day mortality: 4 studies,[@R10] n=1 24 912, RR 0.74, 95% CI 0.56 to 0.98; long-term mortality (≥2 years): 2 studies,[@R29] n=11 161, RR 0.76, 95% CI 0.72 to 0.80) and ADHF (long-term mortality (≥2 years): 6 studies,[@R30] n=11 166, RR 0.67, 95% CI 0.55 to 0.81). Meta-analysis of AMI was homogenous (*I* [@R2] 0%), however, substantial heterogeneity was noted in HF meta-analysis reflecting different settings in the observational studies. The results of meta-analysis are presented as forest plots ([figure 3](#F3){ref-type="fig"}).

![Results of meta-analysis for all-cause mortality. \*Weights are fom random effects analysis. ADHF, acute decompensated heart failure; AMI, acute myocardial infarction; ES, effect size.](bmjopen-2018-028638f03){#F3}

Discussion {#s4}
==========

Main findings {#s4-1}
-------------

This propensity-score matched study of large cohorts of patients hospitalised for AMI or ADHF and a systematic review with meta-analysis provided a rigorous assessment of the association between HLP and long-term all-cause mortality. First, a diagnosis of HLP, compared with no HLP, was associated with 24% and 20% relative risk reduction in all-cause mortality corresponding to 27 and 39 fewer deaths per 1000 person-years after incident AMI and ADHF, respectively. The reduced mortality associated with HLP was robust to adjustment for potential confounder including demographics, clinical characteristics and key CCs. The association was consistent across the following subsets: young and old, male and female, white and non-white, and prevailed across both study cohorts. The reductions in mortality were independent of benefit attributable to statin therapy. Kaplan-Meier estimates suggest that the reduction in cumulative incidence of death from HLP begins immediately after hospitalisation and is maintained into follow-up both in AMI and HF cohorts. Second, we found that cancer, COPD, CKD, diabetes mellitus, HF, or stroke, were all significantly associated with increased long-term mortality. This increased risk was offset by the lower mortality from HLP resulting in attenuation or even a null effect on mortality in patients with AMI or ADHF who had HLP concurrent with other CCs. By comparison, hypertension, while having no effect in HF, was inversely associated with mortality in AMI similar to HLP. The magnitude of mortality reduction associated HLP was enhanced in the presence of HTN after incident AMI and ADHF. Third, the complementary meta-analysis of published observational studies and current study data demonstrated consistent results and provide further evidence that HLP is associated with decreased mortality following incident AMI or ADHF. Multiple sensitivity analyses among patients with available data on BMI, LDL-C, LVEF, levels of sodium, BUN and creatinine all yielded similar results and the association between HLP and mortality remained robust in AMI and ADHF.

Comparative studies {#s4-2}
-------------------

The association of HLP with atherosclerotic cardiovascular disease is largely based on epidemiological studies[@R1] and randomised clinical trials of LDL-C lowering therapy. These studies have important limitations and do not ascertain causal relationship. Although genetic studies are promising and have the potential to address causal relationship of LDL-C with atherosclerotic cardiovascular disease,[@R35] the co-inheritance of other pro-atherogenic factors that affect atherosclerotic cardiovascular disease may not be determined.[@R36] Findings of this study dispute general assumption that HLP is associated with increased mortality. However, several community-based and hospital-based population studies contradict this notion and support our findings. A number of large community-based population studies from Scandinavian countries showed that HLP is inversely related to mortality, particularly in older adults.[@R37] These observations were reproduced in large community-based prospective cohort studies from Japan.[@R41] A prospective observational study found that low LDL-C on admission was associated with a lower 3-year survival after hospitalisation for non-ST elevation myocardial infarction.[@R42] An earlier systematic review found that the mortality risk from HLP decreased with increasing age.[@R5] By comparison, we found that HLP maintained its survival benefit even in older adults, a finding supported by a meta-analysis of 19 cohort studies that showed inverse association between elevated cholesterol and mortality.[@R43] These observations were reinforced by widely used risk-prediction models for AMI and HF in which HLP did not make into the final prediction models[@R12] suggesting a weaker or no association with mortality. An inverse relationship between HLP and mortality was reported for a number of other conditions not the focus of this study.[@R47] Similarly, numerous other conditions such as hypertension, cigarette smoking and factor V Leiden exhibit epidemiological paradox.[@R50] According to epidemiologists, these paradoxes may exemplify collider or index event bias where established risk factor for first occurrence of a disease becomes inversely related after the occurrence of an event.[@R53] The effect of HLP might be concealed in the presence of stronger competing risk factors for mortality.[@R56] Other potential mechanisms include a progressive increase in proportion of deaths from non-cardiovascular conditions with differential association with baseline cholesterol[@R57] and a reverse causation, whereby underlying disease lowers the cholesterol level and increases the risk of death. Numerous investigators argued that low cholesterol represents a biological marker for concurrent cachexia, malnutrition, cancer and other chronic diseases with proven adverse impact on survival.[@R58] However, HLP remained a predictor of lower mortality in several studies that even excluded terminal diseases.[@R43] Our results support the concept of obesity paradox among patients with HF and AMI and findings were consistent with several published studies. Previous studies reported that even healthy subjects with low cholesterol are especially predisposed to infectious diseases.[@R60] Although our findings were adjusted for cancer and numerous other CCs, the potential confounding by undiagnosed cachexia or malnutrition cannot be excluded. Our findings were contradicted by a number of randomised clinical trials and meta-analyses of statin therapy in AMI that demonstrated a dose dependent decrease in the risk of cardiovascular events with reduction in LDL-C level, even down to \<70 mg/dL.[@R6] These discrepant findings are attributable to demographic differences, patient population with lower rates of CCs, shorter follow-up intervals and focus on cardiovascular events including cardiovascular mortality rather than all-cause mortality as the outcome.

Clinical implications {#s4-3}
---------------------

The findings of this study, if validated, should reinforce the importance of HLP in predicting long-term mortality after index AMI or ADHF and potentially provide guidance for subsequent management. HLP can readily be diagnosed and help recognise AMI and HF patients with lower long-term mortality. In these patients, clinical care should not focus on certain lipid targets; rather evidence-based secondary prevention strategies should be initiated. Conversely, patients with AMI and ADHF without HLP may be considered to have increased risk for early mortality and potentially alert providers for close monitoring during hospitalisation and after discharge. Both categories of patients would profit from thoughtful tailored programme with distinctive goals of care for existing CCs.

STRENGTHS AND LIMITATIONS {#s4-4}
-------------------------

This study has several strengths. First, large study cohorts, high level of case ascertainment for incident events and prompt mortality update[@R63] allowed precise estimation of mortality risks. Broader range of patient population, long follow-up extending to 20 years, and all-cause rather than cardiovascular mortality as the primary outcome are additional advantages over randomised controlled trials. Second, propensity-score matching to balance observed patient-characteristics enabled further control of potential differences. Third, we conducted a systematic review and meta-analysis to place the findings of this study in the larger context of existing literature with consistent findings. The study also has a number of important limitations. These included possibility of unmeasured confounders, reliance on ICD-9-CM codes to identify study cohort, Clinical Classifications Software codes to assess coexisting CCs, ascertainment of CCs during index hospitalisation, and lack of data on subsequent acquisition of these conditions during the follow-up. Our study cohorts were homogenous with respect to race and substantially older than those observed in most clinical trials, but, similar to those in many epidemiological studies. The pre-existing HLP and CCs were physician-diagnosed during index hospitalisation rather than being assigned by study investigators. Meta-analysis of ADHF was associated with heterogeneity; nevertheless, the results from all the included studies suggested a reduction in mortality with HLP. Despite some limitations, the findings of the present study may be extended to hospital-based, AMI and ADHF population at large.

Conclusions {#s5}
===========

The current findings, based on large unselected hospital-based patient-populations, provide strong evidence that after incident AMI or ADHF, a diagnosis of HLP, compared with no HLP, was associated with reduced long-term mortality, a longer median survival and modest attenuation of the magnitude of mortality risk associated with other competing CCs. Our data support a protective role for HLP against all-cause mortality following incident AMI and ADHF. Further studies are needed to understand the complex relationship between HLP and mortality, especially in the presence of other competing comorbidities and to define appropriate HLP targets to maximise the benefits.
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